(Q50168144)

English

Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program.

scientific article published in July 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409909%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409909%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

expanded access

1 reference

based on heuristic

inferred from title

malignant pleural mesothelioma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409909%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

author name string

Antoinette J Wozniak

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409909%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Mary-Louise Keohan

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409909%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Helen J Ross

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409909%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Jonathan A Polikoff

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409909%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

David M Mintzer

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409909%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Zhishen Ye

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409909%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Matthew J Monberg

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409909%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Coleman K Obasaju

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409909%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Pemetrexed expanded access program investigators

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409909%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Pasi A Jänne

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409909%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

publication date

1 July 2006

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409909%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Journal of Thoracic Oncology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409909%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409909%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409909%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

506-512

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409909%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Changing trends in US mesothelioma incidence

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2930351-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Analysis of current trends in United States mesothelioma incidence

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2930351-8

7 January 2021

based on heuristic

inferred from DOI database lookup

The European mesothelioma epidemic

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2930351-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Deterioration in lung function following hemithorax irradiation for pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2930351-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Malignant mesothelioma of the pleura: a study of 52 treated and 64 untreated patients

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2930351-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Surgical treatment of malignant pleural mesothelioma: a review

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2930351-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Ifosfamide in malignant mesothelioma: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2930351-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B.

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2930351-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of carboplatin in the management of malignant mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2930351-8

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose methotrexate in the treatment of malignant mesothelioma of the pleura. A phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2930351-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Epirubicin in malignant mesothelioma: a phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2930351-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Etoposide in malignant pleural mesothelioma: two phase II trials of the EORTC Lung Cancer Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2930351-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Mitoxantrone in malignant pleural mesothelioma: a study by the EORTC Lung Cancer Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2930351-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Paclitaxel for malignant pleural mesothelioma: a phase II study of the EORTC Lung Cancer Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2930351-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2930351-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2930351-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2930351-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: results of a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2930351-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of ZD0473 as second-line therapy in mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2930351-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2930351-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2930351-8

7 January 2021

based on heuristic

inferred from DOI database lookup

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2930351-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Raltitrexed-Oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2930351-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Modified RECIST criteria for assessment of response in malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2930351-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1556-0864(15)30351-8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409909%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409909%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50168144&oldid=1585833635"